Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00331500
Status:
COMPLETED
Last Update Posted:
2017-08-14
First Post:
2006-05-30
Brief Title:
Olopatadine 02 for the Treatment of Allergic Conjunctivitis
Sponsor:
Alcon Research
Organization:
Alcon Research
Study Overview
Official Title:
A Comparative Study of Olopatadine 02 Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate that Olopatadine 02 is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None